SNO 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Biotech companies at SNO 2026
Nov 12–15, 2026 Philadelphia, PA ~3k attendees Website
17 biotech companies are at SNO 2026 — 22 presentations on the program. Most represented: Edison Oncology (3 on the program), HDT Bio (2 on the program), SpringWorks Therapeutics (1 on the program). 1 of them have their own page in this guide. As of Nov 12, 2026.
Topic
Top represented
Showing 1–17 of 17 organizations
| Organization | SNO 2026 Attendance |
|---|---|
Edison Oncology Menlo Park, CA | |
A clinical-stage biopharmaceutical company developing biomarker-driven cancer therapies, including brain-penetrant candidates for brain tumors. | Poster Fri Nov 13 7:30–9:30pm Poster Fri Nov 13 7:30–9:30pm |
HDT Bio Seattle, WA | |
A clinical-stage biotechnology company developing immune-based treatments for cancer and infectious diseases, including glioblastoma approaches. | Poster Fri Nov 13 7:30–9:30pm |
SpringWorks Therapeutics Stamford, CT | ◆Platinum Supporter |
A biotechnology company developing targeted medicines for rare tumors and other serious diseases. | Talk Thu Nov 12 6–7:15pm Talk Fri Nov 13 12:21–12:24pm |
CJ Chengdu Jinrui Foundation Biotech Chengdu, China | |
A biotechnology company developing liposomal honokiol, an investigational treatment studied for recurrent glioblastoma. | |
CoSyne Therapeutics London, UK | |
A drug-discovery company using computational methods to develop precision-medicine therapies for neurological and brain diseases. | Talk Sat Nov 14 11:51–11:54am |
FYR Bio Missoula, MT | |
A biotechnology company developing extracellular-vesicle-based liquid biopsy and diagnostic technologies, including tools relevant to brain tumor monitoring. | |
Hemispherian Oslo, Norway | |
A clinical-stage biotechnology company developing small-molecule cancer therapies, including GLIX1 for glioblastoma. | |
IN8bio New York, NY | |
A biotechnology company developing gamma-delta T-cell therapies for cancer, including glioblastoma. | |
Precision NeuroMed Redwood City, CA | |
A clinical-stage biotechnology company developing precision-delivery therapies for glioblastoma and other neurological diseases. | |
RadioMedix Houston, TX | |
A radiopharmaceutical company developing targeted agents for cancer diagnosis, imaging, and radionuclide therapy. | Poster Fri Nov 13 7:30–9:30pm |
UP Oncolytics Milwaukee, WI | |
A biotechnology company developing viral therapies for cancers including glioblastoma. | |
Day One Biopharmaceuticals Brisbane, CA | |
A biopharmaceutical company developing targeted therapies for people with cancer, including pediatric cancers. | Talk Fri Nov 13 7–8:15am Talk Fri Nov 13 6–7:15pm |
Cerenome Houston, TX | ◇Contributing Supporter |
A CNS oncology company combining diagnostics and targeted therapeutics for central nervous system cancers. | |
Fore Biotherapeutics Philadelphia, PA | ◇Contributing Supporter |
A biotechnology company developing targeted cancer therapies, including treatments for tumors with BRAF alterations. | Talk Thu Nov 12 6–7:15pm |
Nuvation Bio New York, NY | ◇Contributing Supporter |
A biopharmaceutical company developing targeted therapies, including treatments for brain and other cancers. | Talk Thu Nov 12 6–7:15pm |
Telix Pharmaceuticals Melbourne, Australia | ◆Platinum Supporter |
A radiopharmaceutical company developing molecular imaging and therapeutic products, including programs relevant to oncology. | Talk Fri Nov 13 6–7:15pm |
Northwest Biotherapeutics Bethesda, MD | ◇Contributing Supporter |
A biotechnology company developing personalized immunotherapies for cancer, including glioblastoma. | Sponsor In the meeting’s sponsor directory, with no session on the public program |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse SNO 2026 by
Organization type
Topic
- Tumor biology: signaling, metabolism, stem cells and the tumor microenvironment 106
- Cancer neuroscience: how neurons and brain tumors interact 54
- Immunobiology, immunotherapy and cell therapies 64
- Experimental therapeutics, drug discovery and resistance, drug delivery and tumor models 105
- Clinical trials, trial design and trials in progress 99
- Molecular pathology, tumor classification and (epi)genomics 102
- Biomarkers and liquid biopsy 53
- Neuroimaging, PET and response assessment 62
- Neurosurgery and surgical therapies 41
- Radiotherapy, radiobiology and radiopharmaceuticals 49
- Pediatric and adolescent and young adult (AYA) brain tumors 55
- Brain and leptomeningeal metastases 27
- Rare CNS tumors and tumor predisposition syndromes 34
- CNS lymphoma and neurohematology 13
- Survivorship, quality of life, cognition, neurologic complications and palliative care 105
- Health disparities, epidemiology and quality improvement 58
Everyone
Not affiliated with or endorsed by the Society for Neuro-Oncology. Submit a correction